Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C P Cross

Showing results (171-180 of 221) with videos related to

Pageof 23
Sort By:
British Journal of Haematology|June 1, 2021
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutationsNicole Naumann, Johannes Lübke, William Shomali, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 19, 2020
Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic MastocytosisJuliana Schwaab, Nicole Cabral do O Hartmann, Nicole Naumann, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Leukemia|October 7, 2021
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusionsElspeth A Bruford, Cristina R Antonescu, Andrew J Carroll, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Blood|August 21, 2013
Comprehensive mutational profiling in advanced systemic mastocytosisJuliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.
Blood|April 2, 2014
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinibChan Y Cheah, Kate Burbury, Jane F Apperley, et al.
International Journal of Molecular Sciences|April 3, 2021
Adverse Prognostic Impact of the <i>KIT</i> D816V Transcriptional Activity in Advanced Systemic MastocytosisNicole Naumann, Johannes Lübke, Sofie Baumann, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Pageof 23

Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
British Journal of Haematology|June 1, 2021
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutationsNicole Naumann, Johannes Lübke, William Shomali, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 19, 2020
Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic MastocytosisJuliana Schwaab, Nicole Cabral do O Hartmann, Nicole Naumann, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Leukemia|October 7, 2021
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusionsElspeth A Bruford, Cristina R Antonescu, Andrew J Carroll, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Blood|August 21, 2013
Comprehensive mutational profiling in advanced systemic mastocytosisJuliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.
Blood|April 2, 2014
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinibChan Y Cheah, Kate Burbury, Jane F Apperley, et al.
International Journal of Molecular Sciences|April 3, 2021
Adverse Prognostic Impact of the <i>KIT</i> D816V Transcriptional Activity in Advanced Systemic MastocytosisNicole Naumann, Johannes Lübke, Sofie Baumann, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Pageof 23